Date: 2018-06-25
Type of information: IPO
Company: Avrobio (USA - MA)
Investors:
Amount: $114.7 million
Funding type: IPO
Planned used:
Others:
- • On June 25, 2018, Avrobio announced the closing of its initial public offering of 6,035,151 shares of common stock at a public offering price of $19.00 per share. This includes the exercise in full by the underwriters of their overallotment option to purchase up to 787,193 additional shares of common stock from the Company at the same price. Including the proceeds from the sale of these additional shares, the company received total gross proceeds of $114.7 million before underwriting discounts and commissions.
- • On June 20, 2018, Avrobio announced the pricing of its initial public offering of 5,247,958 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions, for gross proceeds of $99.7 million. In addition, the company has granted the underwriters a 30-day option to purchase up to 787,193 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVRO" on June 21, 2018. The offering is expected to close on June 25, 2018, subject to customary closing conditions.
- Morgan Stanley, Cowen and Wells Fargo Securities are acting as joint book-running managers for the offering, and Wedbush PacGrow is acting as co-manager for the offering.
Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases
Is general: Yes
